【24h】

Prospective surveillance of vancomycin-resistant enterococci in a neonatal intensive care unit.

机译:在新生儿重症监护病房中对耐万古霉素的肠球菌进行前瞻性监测。

获取原文
获取原文并翻译 | 示例
           

摘要

A point-prevalence study of vancomycin-resistant enterococci colonization of the gastrointestinal tract in an Israeli hospital revealed that 14.7% of the 320 inpatients were colonized. Vancomycin-resistant enterococci colonization was detected in most departments except the neonatal intensive care unit. Hence, a prospective longitudinal study of the prevalence of vancomycin-resistant enterococci colonization in the neonatal intensive care unit was conducted. A rectal swab was obtained from every newborn on admission to the neonatal intensive care unit and once weekly thereafter until the patient was discharged. Enterococci were isolated and tested for susceptibility to vancomycin. A total of 84 neonates were enrolled and monitored on average for 3 weeks (SD +/- 3.9, range 1-20 weeks). Mean gestational age was 35.7 weeks (SD +/- 3.9, range 25-42 weeks), and mean birth weight was 2.4 kg (SD +/- 0.9, range 0.45-4.1 kg). Most patients had one or more of the known risk factors associated with colonization with vancomycin-resistant enterococci. Eighty percent of the patients received antibiotics during the study, and 14.3% received vancomycin. The median duration of vancomycin treatment was 12.5 days (SD +/- 16.8, range 5-55 days). Fifty-one of 84 (61%) patients acquired enterococci sensitive to vancomycin during the study period, but no newborn had vancomycin-resistant enterococci. Possible explanations for this finding may be physical isolation of the neonatal intensive care unit from the rest of the hospital, intrinsic differences in the bowel milieu of this age group and the lack of exposure to food and other environmental sources of vancomycin-resistant enterococci from the community.
机译:在以色列一家医院中对万古霉素耐药的肠球菌在胃肠道中的定点流行研究显示,在320名住院患者中有14.7%被定殖。除新生儿重症监护病房外,大多数部门都检测到耐万古霉素的肠球菌定植。因此,对新生儿重症监护病房中耐万古霉素的肠球菌定植的流行进行了前瞻性纵向研究。在新生儿重症监护病房入院时从每个新生儿获得直肠拭子,此后每周一次,直到患者出院为止。分离肠球菌并测试对万古霉素的敏感性。总共纳入84名新生儿,平均监测3周(SD +/- 3.9,范围1-20周)。平均胎龄为35.7周(标准差+/- 3.9,范围25-42周),平均出生体重为2.4千克(标准差+/- 0.9,范围为0.45-4.1 kg)。大多数患者具有与耐万古霉素肠球菌定植有关的一种或多种已知危险因素。在研究期间,有80%的患者接受了抗生素治疗,有14.3%的患者接受了万古霉素治疗。万古霉素治疗的中位时间为12.5天(SD +/- 16.8,范围5-55天)。在研究期间,84名患者中有51名(61%)获得了对万古霉素敏感的肠球菌,但没有新生儿出现耐万古霉素的肠球菌。这一发现的可能解释可能是新生儿重症监护病房与医院其他地方的物理隔离,该年龄组肠道环境的内在差异以及从食物和其他环境来源获得的耐万古霉素肠球菌缺乏社区。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号